Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Innovent, Alector Enter Oncology Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Innovent, Alector Enter Oncology Alliance

To develop and commercialize an anti-SIRP-alpha antibody (Alector's AL008) for the treatment of oncology indications in China.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Innovent, a biopharmaceutical company that develops medicines for oncology, autoimmune, metabolic and other diseases, and Alector, Inc., a clinical stage biotechnology company developing therapeutics focused on the immune system, have entered into a licensing agreement to develop and commercialize an anti-SIRP-alpha antibody (Alector’s AL008) for the treatment of oncology indications in China.

AL008 is Alector’s novel antibody targeting the CD47-SIRP-alpha pathway, a potent survival pathway co-opted by tumors to evade the innate immune system. AL008 is a first-in-class SIRP-alpha inhibitor with a unique dual mechanism of action that non-competitively antagonizes the CD47-SIRP-alpha pathway by inducing the internalization and degradation of the inhibitory receptor on macrophages to relieve immune suppression (a “don’t eat me signal”) while also engaging Fc gamma to promote immuno-stimulatory pathways that drive anti-tumor immunity.

Under the agreement, Innovent will lead the development and commercialization of the molecule in China, including the manufacturing of the product. Alector will lead development of AL008 outside of China. Financial terms are not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics